Purdue Pharma L.P.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Purdue Pharma L.P.
Chiesi Returns To Respiratory Roots With Affibody Pact
A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.
EMA Backs Approval For Eight New Drugs But Rejects Lagevrio For COVID-19
Janssen’s Akeega is among the latest drugs that the European Medicines Agency says should be approved for use in the EU. Meanwhile, MSD/Ridgeback Biotherapeutics plan to appeal the agency’s rejection of their COVID-19 treatment.
EU Decision Time For Zejula/Zytiga Combo Therapy, Vadadustat & Other Drugs
The European Medicines Agency’s human medicines committee, the CHMP, is this week deciding whether to back the approval of a number of new drugs.
Nasal Naloxone On Brink Of OTC Among Additional Opioid Overdose Options On US FDA's Plate
Upcoming goal dates for Emergent’s Narcan and Harm Reduction Therapeutics’ RiVive will test the US FDA’s efforts to nurture the over-the-counter naloxone switch, followed by decisions on higher strength nasal opioid antagonist products from Opiant and Orexo to address fentanyl and other synthetic opioids.
- Drug Delivery
- OTC, Consumer
- Controlled Release
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Imbrium Therapeutics L.P.
- Adlon Therapeutics L.P
- Rhodes Pharmaceuticals LP
- CoCensys Inc
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.